Literature DB >> 4009220

Criteria of tumor response used in clinical trials of chemotherapy.

K Tonkin, D Tritchler, I Tannock.   

Abstract

We have studied 61 published reports of trials of cancer chemotherapy to evaluate the criteria for tumor response that were used and the adequacy of their description in the publication. Our sample comprised recent articles published in three major journals that addressed the influence of chemotherapy on patients with recurrent or metastatic colorectal cancer, non-small cell lung cancer, and head and neck cancer. Incomplete information was sought through a questionnaire mailed to the senior author of each paper, and 48 of them responded. We conclude that: no article contained all of the information required to define precisely criteria for tumor responses; criteria for tumor response are variable; and differences in response criteria contribute to the wide variation in reported rates of tumor response. Meaningful intercomparison of clinical trials will require the establishment of uniform criteria for assessing and reporting the response of tumors to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009220     DOI: 10.1200/JCO.1985.3.6.870

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Reproducibility of linear tumor measurements using PACS: comparison of caliper method with edge-tracing method.

Authors:  Wayne L Monsky; Vassilios Raptopoulos; Mary T Keogan; David Doty; Ihab Kamel; Chun Sam Yam; Bernard J Ransil
Journal:  Eur Radiol       Date:  2003-12-05       Impact factor: 5.315

Review 2.  Cytotoxic chemotherapy for common adult malignancies: "the emperor's new clothes" revisited?

Authors:  J H Kearsley
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-04

Review 3.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

4.  Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Authors:  Nathan R Foster; Yingwei Qi; Qian Shi; James E Krook; John W Kugler; James R Jett; Julian R Molina; Steven E Schild; Alex A Adjei; Sumithra J Mandrekar
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

5.  Response criteria for intraocular retinoblastoma: RB-RECIST.

Authors:  Jesse L Berry; Francis L Munier; Brenda L Gallie; Ashley Polski; Sona Shah; Carol L Shields; Dan S Gombos; Kathleen Ruchalski; Christina Stathopoulos; Rachana Shah; Rima Jubran; Jonathan W Kim; Prithvi Mruthyunjaya; Brian P Marr; Matthew W Wilson; Rachel C Brennan; Guillermo L Chantada; Murali M Chintagumpala; A Linn Murphree
Journal:  Pediatr Blood Cancer       Date:  2021-02-23       Impact factor: 3.167

6.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.

Authors:  Colleen M Costelloe; Hubert H Chuang; John E Madewell; Naoto T Ueno
Journal:  J Cancer       Date:  2010-06-28       Impact factor: 4.207

7.  When progressive disease does not mean treatment failure: reconsidering the criteria for progression.

Authors:  Geoffrey R Oxnard; Michael J Morris; F Stephen Hodi; Laurence H Baker; Mark G Kris; Alan P Venook; Lawrence H Schwartz
Journal:  J Natl Cancer Inst       Date:  2012-08-27       Impact factor: 13.506

8.  Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma.

Authors:  P Bougnoux; E Germain; V Chajès; B Hubert; C Lhuillery; O Le Floch; G Body; G Calais
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Significance of different response evaluation criteria in predicting progression-free survival of lung cancer with certain imaging characteristics.

Authors:  Dengxia Yang; Gavitt Woodard; Chan Zhou; Xinyue Wang; Zhujun Liu; Zhaoxiang Ye; Kai Li
Journal:  Thorac Cancer       Date:  2016-06-21       Impact factor: 3.500

10.  Association of PTP1B with Outcomes of Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy.

Authors:  Monica M Rivera Franco; Eucario Leon Rodriguez; Braulio Martinez Benitez; Luisa G Villanueva Rodriguez; Maria de la Luz Sevilla Gonzalez; Alejandra Armengol Alonso
Journal:  Breast Cancer (Auckl)       Date:  2016-11-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.